Compare Quest Diagnostics Inc (DGX) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Freshworks Inc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Freshworks Inc trades at $10.61 (market cap $2.89B). The key difference: Quest Diagnostics Inc is far larger — about 7.9× Freshworks Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| DGX | FRSH | |
|---|---|---|
Market Cap | $22.80B | $2.89B |
Sector | Health | Technology |
52-Week High | $216.02 | $14.77 |
52-Week Low | $166.42 | $6.88 |
Enterprise Value | $28.82B | $2.15B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Freshworks (FRSH) trades at $10.83, up 4.54% today, with a bullish technical signal from moving averages. The company shows strong fundamental improvement, with revenue growing from $498M in 2022 to $839M in 2025 and achieving profitability with a net income margin of 20.69%. Recent news highlights AI product launches and a strategic pivot to employee experience, with Q2 2026 earnings due August 4, 2026.
The outlook is positive given consistent revenue growth, high gross margins, and analyst consensus pointing to a 26% upside. Risks include execution of the new strategic focus and competitive pressures in the SaaS sector. The stock presents a value opportunity with a P/E of 17.63, below software industry averages, supported by improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
